NR1H4 and metabolic dysfunction-associated steatohepatitis: Synthetic FXR agonists, including steroidal and nonsteroidal ligands, for the treatment of liver diseases, such as nonalcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC), are currently under development.